{"schema_version":"secwatch.filing_event.v1","accession":"0001599298-26-000067","form_type":"8-K","ticker":"SMMT","cik":"0001599298","company_name":"Summit Therapeutics Inc.","filed_at":"2026-07-23T20:07:41+00:00","discovered_at":"2026-07-23T20:09:00.244230+00:00","generated_at":"2026-07-23T20:09:24.654319+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Summit Therapeutics Q2 2026: Cash $690.7M; HARMONi-6 OS benefit; PDUFA Nov 14","bullets":["Cash and investments $690.7M at June 30, 2026; raised $230.8M via ATM in Q2 and $68.4M post-quarter.","GAAP net loss $215.7M ($0.28/share); Non-GAAP net loss $147.0M ($0.19/share) vs $86.9M ($0.12) in Q2 2025.","HARMONi updated OS: HR 0.76 in full ITT, consistent in western and Asian patients; BLA PDUFA Nov 14, 2026.","HARMONi-6 (Akeso) showed OS benefit over tislelizumab (HR 0.66, p=0.0017) in 1L squamous NSCLC.","Sold ridinilazole to Biossil for $500K upfront + up to $104.5M milestones; clinical collaborations with Arcus, RevMed, GSK."],"urls":{"canonical":"https://secwatch.observer/filing/0001599298-26-000067","json":"https://secwatch.observer/filing/0001599298-26-000067.json","markdown":"https://secwatch.observer/filing/0001599298-26-000067.md","text":"https://secwatch.observer/filing/0001599298-26-000067.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1599298/000159929826000067/0001599298-26-000067-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1599298/000159929826000067/smmt-20260723.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-23T20:09:24.654319+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}